We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -7.69% | 6.00 | 5.00 | 7.00 | 6.50 | 6.00 | 6.50 | 24,715 | 16:02:50 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:0254K
ReGen Therapeutics PLC
14 April 2003
ReGen Therapeutics Plc
14 April 2003
Immediate Release
ReGen Therapeutics Plc
SUBSTANTIAL SHAREHOLDING
London, UK - 14 April, 2003: ReGen Therapeutics Plc (the "Company") announces
that on 14 April 2003 it received notification from Hoodless Brennan & Partners
Plc ("Hoodless") that, following an acquisition by Hoodless of 32,793,333
ordinary shares of the Company on 10 April 2003, Hoodless's shareholding in the
Company was 23.27% of the issued share capital of the Company.
Further, the Company received notification from Hoodless on 14 April 2003 that,
following a disposal by it of 12,581,666 ordinary shares of the Company on 10
April 2003, and a further disposal of 20,055,500 ordinary shares of the Company
on 11 April 2003, its shareholding is now less than 3% of the issued share
capital of the Company.
For further information, please contact:
Andrew Marshall Tel. 020 7489 2033
Marshall Robinson Roe
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAKLLFDFDEFE
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
